{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T16:44:47Z","timestamp":1758818687014,"version":"3.33.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"22","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T00:00:00Z","timestamp":1723420800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.vaccine.2024.126223","type":"journal-article","created":{"date-parts":[[2024,8,15]],"date-time":"2024-08-15T08:43:30Z","timestamp":1723711410000},"page":"126223","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy and safety of Abdala COVID-19 subunit vaccine in children and adolescents: An open-label, single-arm, phase 2 trial (ME\u00d1IQUE)"],"prefix":"10.1016","volume":"42","author":[{"given":"Francisco","family":"Hern\u00e1ndez-Bernal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Enrique","family":"Noa-Romero","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joel","family":"Quintana-Guerra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cristina O.","family":"Ch\u00e1vez-Chong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yenima","family":"Mart\u00edn-Bauta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura","family":"Alvar\u00e9-Alvar\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alena","family":"Salvato-Due\u00f1as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danusia","family":"Felipe-Mallea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mairalys","family":"Porta-D\u00edaz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Otto","family":"Cruz-Sui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Urrutia-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klaudia","family":"Urrutia-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 L.","family":"Rodr\u00edguez-Reinoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marel","family":"Alonso-Vald\u00e9s","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zurina","family":"Cinza-Est\u00e9vez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aylin","family":"Rodr\u00edguez-Triana","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yolanda","family":"Cruz-G\u00f3mez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miladys","family":"Limonta-Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mireida","family":"Rodr\u00edguez-Acosta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Ayala-\u00c1vila","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Verena L.","family":"Muzio-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2024.126223_bb0005","unstructured":"World Health Organization. WHO coronavirus (COVID-19) dashboard. Published March 9, 2022. Accessed March 31, 2024. https:\/\/covid19.who.int\/."},{"key":"10.1016\/j.vaccine.2024.126223_bb0010","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1002\/jmv.26398","article-title":"A systematic review and meta-analysis of children with coronavirus disease 2019 (COVID-19)","volume":"93","author":"Cui","year":"2021","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2024.126223_bb0015","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2020.11.016","article-title":"Tri-State Pediatric COVID-19 Research Consortium. Severe acute respiratory syndrome coronavirus 2 clinical syndromes and predictors of disease severity in hospitalized children and youth","volume":"230","author":"Fernandes","year":"2021","journal-title":"J Pediatr"},{"key":"10.1016\/j.vaccine.2024.126223_bb0020","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMp2020076","article-title":"Accelerating development of SARS-CoV-2 vaccines \u2014 the role for controlled human infection models","author":"Deming","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.vaccine.2024.126223_bb0025","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"China novel coronavirus investigating and research team. a novel coronavirus from patients with pneumonia in china 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"issue":"47","key":"10.1016\/j.vaccine.2024.126223_bb0030","first-page":"70772","article-title":"Current clinical status of new COVID-19 vaccines and immunotherapy","volume":"29","author":"Nagpal","year":"2022","journal-title":"Environ Sci Pollut Res Int"},{"issue":"12","key":"10.1016\/j.vaccine.2024.126223_bb0035","article-title":"Efficacy and safety of COVID-19 vaccines","volume":"12","author":"Gra\u00f1a","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"author":"Interim statement on COVID-19 vaccination for children, 11 August 2022","key":"10.1016\/j.vaccine.2024.126223_bb0040"},{"author":"European Centre for Disease Prevention and Control","key":"10.1016\/j.vaccine.2024.126223_bb0045"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126223_bb0050","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0935","article-title":"Assessment of clinical effectiveness of BNT162b2 COVID-19 vaccine in US adolescents","volume":"5","author":"Oliveira","year":"2022","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126223_bb0055","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa2116298","article-title":"Evaluation of the BNT162b2 Covid-19 vaccine in children 5 to 11 Years of age","volume":"386","author":"Walter","year":"2022","journal-title":"N Engl J Med"},{"author":"WHO","key":"10.1016\/j.vaccine.2024.126223_bb0060"},{"issue":"72","key":"10.1016\/j.vaccine.2024.126223_bb0065","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.nbt.2022.08.002","article-title":"An engineered SARS-CoV-2 receptor-binding domain produced in Pichia pastoris as a candidate vaccine antigen","volume":"25","author":"Limonta-Fern\u00e1ndez","year":"2022","journal-title":"N Biotechnol"},{"key":"10.1016\/j.vaccine.2024.126223_bb0070","first-page":"21","article-title":"Demonstrating \u201cAbdala\u201d subunit vaccine thermostability","author":"Izquierdo","year":"2022","journal-title":"BioProcess J"},{"key":"10.1016\/j.vaccine.2024.126223_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101383","article-title":"Safety, tolerability, and immunogenicity of a SARS-CoV-2 recombinant spike RBD protein vaccine: a randomised, double-blind, placebo-controlled, phase 1-2 clinical trial (ABDALA Study)","volume":"46","author":"Hern\u00e1ndez-Bernal","year":"2022","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.vaccine.2024.126223_bb0080","article-title":"A phase 3, randomised, double-blind, placebo-controlled clinical trial evaluation of the efficacy and safety of a SARS-CoV-2 recombinant spike RBD protein vaccine in adults (ABDALA-3 Study)","volume":"21","author":"Hern\u00e1ndez-Bernal","year":"2023","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.vaccine.2024.126223_bb0085","article-title":"Cuban Abdala vaccine: effectiveness in preventing severe disease and death from COVID-19 in Havana, Cuba; a cohort study","author":"M\u00e1s-Bermejo","year":"2022","journal-title":"Lancet Reg Health Am"},{"key":"10.1016\/j.vaccine.2024.126223_bb0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2023.102160","article-title":"Immunogenicity and Safety assessment of a SARS-CoV-2 recombinant spike RBD protein vaccine (Abdala) in paediatric ages 3 to 18 years old: a double-blinded, multicentre, randomised, phase 1\/2 clinical trial (ISMAELILLO study)","volume":"63","author":"Cinza-Est\u00e9vez","year":"2023","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.vaccine.2024.126223_bb0095","article-title":"Guidelines on clinical evaluation of vaccines: regulatory expectations","volume":"No. 1004","author":"Annex 9.","year":"2017","journal-title":"WHO Tech Rep Series"},{"year":"2022","series-title":"Considerations for evaluation of COVID-19 vaccines. Points to consider for manufacturers of COVID-19 vaccines","author":"WHO","key":"10.1016\/j.vaccine.2024.126223_bb0100"},{"year":"2019","series-title":"Causality assessment of an adverse event following immunization (AEFI): user manual for the revised WHO classification second edition, 2019 update","author":"World Health Organization","key":"10.1016\/j.vaccine.2024.126223_bb0105"},{"issue":"10","key":"10.1016\/j.vaccine.2024.126223_bb0110","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1002\/jmv.25986","article-title":"Evaluation of SARS-CoV-2 neutralizing antibodies using a CPE-based colorimetric live virus micro-neutralization assay in human serum samples","volume":"92","author":"Manenti","year":"2020","journal-title":"J Med Virol"},{"key":"10.1016\/j.vaccine.2024.126223_bb0115","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/sim.4780091208","article-title":"Test statistics and sample size formulae for comparative binomial trials with null hypothesis of non-zero risk difference or non-unity relative risk","volume":"9","author":"Farrington","year":"1990","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2024.126223_bb0120","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/sim.4780040211","article-title":"Comparative analysis of two rates","volume":"4","author":"Miettinen","year":"1985","journal-title":"Stat Med"},{"key":"10.1016\/j.vaccine.2024.126223_bb0125","series-title":"Statistical Yearbook of Health 2022. Havana: Directorate of Medical Records and Health Statistics","article-title":"Ministry of Public Health","author":"Cuba","year":"2023"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126223_bb0130","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1056\/NEJMoa2107456","article-title":"Safety, immunogenicity, and efficacy of the BNT162b2 Covid-19 vaccine in adolescents","volume":"385","author":"Frenck","year":"2021","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.vaccine.2024.126223_bb0135","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1056\/NEJMoa2203315","article-title":"Evaluation of mRNA-1273 Covid-19 vaccine in children 6 to 11 years of age","volume":"386","author":"Creech","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126223_bb0140","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1001\/jama.2021.24110","article-title":"Myocarditis cases reported after mRNA-based COVID-19 vaccination in the US from December 2020 to august 2021","volume":"327","author":"Oster","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.vaccine.2024.126223_bb0145","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2021-052478","article-title":"Symptomatic acute myocarditis in 7 adolescents after Pfizer-BioNTech COVID-19 vaccination","volume":"148","author":"Marshall","year":"2021","journal-title":"Pediatrics"},{"key":"10.1016\/j.vaccine.2024.126223_bb0150","doi-asserted-by":"crossref","first-page":"e163","DOI":"10.1016\/j.clinthera.2021.04.010","article-title":"Exploration and ethical analysis of open-label pediatric vaccine trials in a pandemic","volume":"43","author":"Wolfe","year":"2021","journal-title":"Clin Ther"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126223_bb0155","article-title":"Emergence and evolution of SARS-CoV-2 genetic variants during the Cuban epidemic","volume":"2","author":"Guzm\u00e1n","year":"2022","journal-title":"J Clin Virol Plus"},{"issue":"3\u20134","key":"10.1016\/j.vaccine.2024.126223_bb0160","article-title":"Epidemiological characterization of patients in the first eight weeks following detection of SARS-CoV-2 B.1.1.529 (omicron) variant in Cuba","volume":"24","author":"P\u00e9rez-Santos","year":"2022","journal-title":"MEDICC Rev"},{"key":"10.1016\/j.vaccine.2024.126223_bb0165","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2024.1338208","article-title":"The effect of COVID-19 vaccine to the omicron variant in children and adolescents: a systematic review and meta-analysis","volume":"12","author":"Lu","year":"2024","journal-title":"Front Public Health"},{"key":"10.1016\/j.vaccine.2024.126223_bb0170","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.ijid.2021.04.082","article-title":"Vaccination against SARS-CoV-2 should be included in childhood vaccination programs","volume":"106","author":"Petensen","year":"2021","journal-title":"Int J Infect Dis"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24009058?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24009058?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T22:10:14Z","timestamp":1737583814000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24009058"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":34,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["S0264410X24009058"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126223","relation":{},"ISSN":["0264-410X"],"issn-type":[{"type":"print","value":"0264-410X"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of Abdala COVID-19 subunit vaccine in children and adolescents: An open-label, single-arm, phase 2 trial (ME\u00d1IQUE)","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126223","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Centre for Genetic Engineering and Biotechnology, Havana, Cuba. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126223"}}